A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
Status:
Completed
Trial end date:
2018-05-09
Target enrollment:
Participant gender:
Summary
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy
Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
Phase:
Phase 2
Details
Lead Sponsor:
Gemphire Therapeutics, Inc. NeuroBo Pharmaceuticals Inc.